Literature DB >> 11904317

p16(Ink4a) in melanocyte senescence and differentiation.

Elena V Sviderskaya1, Simon P Hill, Tracy J Evans-Whipp, Lynda Chin, Seth J Orlow, David J Easty, Sok Ching Cheong, David Beach, Ronald A DePinho, Dorothy C Bennett.   

Abstract

BACKGROUND: The Ink4a-Arf tumor suppressor locus encodes two growth inhibitors, p16 and Arf, both of which are also implicated as effectors in cellular senescence. Because human germline defects in the INK4A-ARF locus are associated with familial melanoma, melanocytes may have unusual INK4A-ARF functions or controls of cell senescence. Because senescence is believed to be an anticancer mechanism, we investigated the role of Ink4a-Arf and its individual components in melanocyte senescence.
METHODS: Melanocytes were cultured from littermate mice with zero, one, or two functional copies of the Ink4a-Arf locus. Senescence was evaluated by cumulative population doubling curves and by the assessment of acidic beta-galactosidase (an indicator of senescence) expression. Pigmentation and cell size were evaluated by spectrophotometry and microscopy. p16 and Arf expression in primary and spontaneously immortalized melanocyte or melanocyte precursor cell lines were evaluated by immunoblotting. Retroviral vectors containing normal p16 and Arf complementary DNAs were used to restore expression of these genes in Ink4a-Arf(-/-) melanocytes.
RESULTS: Wild-type melanocytes (i.e., Ink4a-Arf(+/+)) senesced within 4-5 weeks of culture. Ink4a-Arf(-/-) melanocytes did not senesce and readily became immortal. Ink4a-Arf(+/-) melanocytes showed defective senescence. Senescent Ink4a-Arf(+/+) melanocytes were heavily pigmented, but Ink4a-Arf(+/-) and Ink4a-Arf(-/-) melanocytes were less pigmented. All of six spontaneously immortalized melanocyte or melanocyte precursor lines from Ink4a-Arf(+/+) mice lacked p16 protein expression, although most retained Arf protein expression. After restoration of p16 but not Arf expression, Ink4a-Arf(-/-) melanocytes stopped growing, became highly melanized, and expressed acidic beta-galactosidase. By contrast, restoration of Arf but not p16 expression led to cell death without evidence of senescence.
CONCLUSION: Normal mouse melanocyte senescence and associated pigmentation require both copies of Ink4a-Arf and appear to depend more on p16 than on Arf function. Mutations of the INK4A-ARF locus may favor tumorigenesis from melanocytes by impairing senescence, cell differentiation, and (where ARF is disrupted) cell death.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11904317     DOI: 10.1093/jnci/94.6.446

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  72 in total

1.  Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway.

Authors:  Janet L Maldonado; Luika Timmerman; Jane Fridlyand; Boris C Bastian
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

2.  Assembly and architecture of biogenesis of lysosome-related organelles complex-1 (BLOC-1).

Authors:  Hyung Ho Lee; Daniel Nemecek; Christina Schindler; William J Smith; Rodolfo Ghirlando; Alasdair C Steven; Juan S Bonifacino; James H Hurley
Journal:  J Biol Chem       Date:  2011-12-27       Impact factor: 5.157

3.  LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.

Authors:  Wenjin Liu; Kimberly B Monahan; Adam D Pfefferle; Takeshi Shimamura; Jessica Sorrentino; Keefe T Chan; David W Roadcap; David W Ollila; Nancy E Thomas; Diego H Castrillon; C Ryan Miller; Charles M Perou; Kwok-Kin Wong; James E Bear; Norman E Sharpless
Journal:  Cancer Cell       Date:  2012-06-12       Impact factor: 31.743

4.  Rab8 regulates the actin-based movement of melanosomes.

Authors:  Marion L Chabrillat; Claire Wilhelm; Christina Wasmeier; Elena V Sviderskaya; Daniel Louvard; Evelyne Coudrier
Journal:  Mol Biol Cell       Date:  2005-01-26       Impact factor: 4.138

5.  Localization to mature melanosomes by virtue of cytoplasmic dileucine motifs is required for human OCA2 function.

Authors:  Anand Sitaram; Rosanna Piccirillo; Ilaria Palmisano; Dawn C Harper; Esteban C Dell'Angelica; M Vittoria Schiaffino; Michael S Marks
Journal:  Mol Biol Cell       Date:  2008-12-30       Impact factor: 4.138

6.  ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence.

Authors:  Linan Ha; Takeshi Ichikawa; Miriam Anver; Ross Dickins; Scott Lowe; Norman E Sharpless; Paul Krimpenfort; Ronald A Depinho; Dorothy C Bennett; Elena V Sviderskaya; Glenn Merlino
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

7.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Authors:  Mitchell Cheung; Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

8.  Gpnmb is a melanoblast-expressed, MITF-dependent gene.

Authors:  Stacie K Loftus; Anthony Antonellis; Ivana Matera; Gabriel Renaud; Laura L Baxter; Duncan Reid; Tyra G Wolfsberg; Yidong Chen; Chenwei Wang; Megana K Prasad; Seneca L Bessling; Andrew S McCallion; Eric D Green; Dorothy C Bennett; William J Pavan
Journal:  Pigment Cell Melanoma Res       Date:  2008-11-01       Impact factor: 4.693

9.  Agouti protein, mahogunin, and attractin in pheomelanogenesis and melanoblast-like alteration of melanocytes: a cAMP-independent pathway.

Authors:  Tokimasa Hida; Kazumasa Wakamatsu; Elena V Sviderskaya; Andrew J Donkin; Lluis Montoliu; M Lynn Lamoreux; Bin Yu; Glenn L Millhauser; Shosuke Ito; Gregory S Barsh; Kowichi Jimbow; Dorothy C Bennett
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-26       Impact factor: 4.693

10.  Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.

Authors:  David Dankort; David P Curley; Robert A Cartlidge; Betsy Nelson; Anthony N Karnezis; William E Damsky; Mingjian J You; Ronald A DePinho; Martin McMahon; Marcus Bosenberg
Journal:  Nat Genet       Date:  2009-03-12       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.